These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 21810725)

  • 1. Blood pressure target in chronic kidney disease and proteinuria as an effect modifier.
    Schrier RW; Lumlertgul N
    Ann Intern Med; 2011 Aug; 155(3):207-8; author reply 208. PubMed ID: 21810725
    [No Abstract]   [Full Text] [Related]  

  • 2. [Predicting diabetic nephropathy].
    Mogensen CE; Christensen CK
    Journ Annu Diabetol Hotel Dieu; 1984; ():333-49. PubMed ID: 6399537
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypertension in diabetes mellitus.
    Hasslacher C; Ritz E; Tschöpe W; Gallasch G; Mann JF
    Kidney Int Suppl; 1988 Sep; 25():S133-7. PubMed ID: 3184604
    [No Abstract]   [Full Text] [Related]  

  • 4. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The kidney as a target organ in diabetic patients with arterial hypertension].
    Viberti G
    Drugs; 2003; 63 Spec No 1():31-7. PubMed ID: 12708880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function.
    Saelen MG; Prøsch LK; Gudmundsdottir H; Dyrbekk D; Helge Hunderi O; Arnesen E; Paulsen D; Skjønsberg H; Os I
    Blood Press; 2005; 14(3):170-6. PubMed ID: 16036497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieved vs initial blood pressure in predicting renal outcomes.
    Onuigbo MA
    Arch Intern Med; 2004 Jan; 164(2):223; author reply 223-4. PubMed ID: 14744850
    [No Abstract]   [Full Text] [Related]  

  • 10. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier.
    Upadhyay A; Earley A; Haynes SM; Uhlig K
    Ann Intern Med; 2011 Apr; 154(8):541-8. PubMed ID: 21403055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of end-stage renal disease due to type 2 diabetes.
    Hostetter TH
    N Engl J Med; 2001 Sep; 345(12):910-2. PubMed ID: 11565525
    [No Abstract]   [Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibition: facts and fiction.
    Tamimi N; El Nahas AM
    Nephron; 2000 Apr; 84(4):299-304. PubMed ID: 10754405
    [No Abstract]   [Full Text] [Related]  

  • 13. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension: a review and rationale of treatment.
    Copley JB; Rosario R
    Dis Mon; 2005; 51(10-11):548-614. PubMed ID: 16360376
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of dietary protein restriction and influence of proteinuria on progression of type 2 diabetic renal failure].
    Okada T; Matsumoto H; Nakao T; Nagaoka Y; Shino T; Yoshino M; Hidaka H; Kanazawa Y
    Nihon Jinzo Gakkai Shi; 2000 Jul; 42(5):365-73. PubMed ID: 10998917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical manifestations and natural history of diabetic kidney disease.
    Ritz E
    Med Clin North Am; 2013 Jan; 97(1):19-29. PubMed ID: 23290727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lercanidipine in diabetic patients with renal failure].
    Robles NR; Pastor L; Manjón M; Ocón J; Gómez Campderá F; Herrera J; Villatoro J; Calls J; Torrijos J; Rodríguez Villareal I; Rodríguez Martínez MA; Méndez ML; Morey A; Martínez Fernández J; Marco J; Liébana A; Rincón B; Tornero F
    Nefrologia; 2004; 24(4):338-43. PubMed ID: 15455493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of diabetic nephropathy: a rational approach based on its pathophysiology.
    Tuttle KR; DeFronzo RA; Stein JH
    Semin Nephrol; 1991 Mar; 11(2):220-35. PubMed ID: 1674623
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Blankfield RP
    N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11870250
    [No Abstract]   [Full Text] [Related]  

  • 20. Diagnosis and Management of Type 2 Diabetic Kidney Disease.
    Doshi SM; Friedman AN
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1366-1373. PubMed ID: 28280116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.